Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models

K. Fazekas, E. Rásó, M. Zaránd, J. Dudás, J. Tímár

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: We have postulated that the peptide domain(s) of the heparin-binding cytokine(s) might have biological activity, which theoretically could be exploited for modulation of the biological behavior of cancer cells. Materials and Methods: We used HGF as a model heparin-binding cytokine and synthesized two HGF β-chain domains, HHRGK (HGP1) and RYRNKH (HGP2), as well as four variants. As target cells, we used three cancer cell lines (HT25 human colonic, HT168-M1/9 human melanoma and 3LL-HH murine lung carcinoma) all characterized by strong liver metastatic potentials. The effects of peptides on cell proliferation, tumor growth and liver metastasis were evaluated. Results: All the basic penta- or hexapeptides exhibited similar antiproliferative effects in vitro in a dose range of 100-1000 ng/ml. Meanwhile, none of the HGP peptides exhibited significant antitumoral effects on the primary spleen tumors in the form of systemic treatment. However, systemic treatment with HGP1, but not with HGP2, applied at the early phase of the dissemination process, showed an inhibitory effect on liver metastatization of all the tumor lines studied. Furthermore, one out of the four hexapeptides, BP4 (KRKRKR), had similar activity. Conclusion: Recent data on the antiangiogenic effects of these basic peptides partially explain the in vivo antimetastatic activity. We suggest the small basic penta-hexapeptides as a new class of biological response modifiers which can modulate the metastatic process.

Original languageEnglish
Pages (from-to)2575-2579
Number of pages5
JournalAnticancer Research
Volume22
Issue number5
Publication statusPublished - Sep 2002

Fingerprint

Neoplasm Metastasis
Peptides
Liver
Rubiaceae
Neoplasms
Heparin
Cytokines
Immunologic Factors
Melanoma
Spleen
Cell Proliferation
Carcinoma
Cell Line
Lung
Growth

Keywords

  • Basic peptide
  • HGF-β-chain
  • Liver metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. / Fazekas, K.; Rásó, E.; Zaránd, M.; Dudás, J.; Tímár, J.

In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 2575-2579.

Research output: Contribution to journalArticle

@article{de93385a3a0941f781f35c14fc14e7c1,
title = "Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models",
abstract = "Purpose: We have postulated that the peptide domain(s) of the heparin-binding cytokine(s) might have biological activity, which theoretically could be exploited for modulation of the biological behavior of cancer cells. Materials and Methods: We used HGF as a model heparin-binding cytokine and synthesized two HGF β-chain domains, HHRGK (HGP1) and RYRNKH (HGP2), as well as four variants. As target cells, we used three cancer cell lines (HT25 human colonic, HT168-M1/9 human melanoma and 3LL-HH murine lung carcinoma) all characterized by strong liver metastatic potentials. The effects of peptides on cell proliferation, tumor growth and liver metastasis were evaluated. Results: All the basic penta- or hexapeptides exhibited similar antiproliferative effects in vitro in a dose range of 100-1000 ng/ml. Meanwhile, none of the HGP peptides exhibited significant antitumoral effects on the primary spleen tumors in the form of systemic treatment. However, systemic treatment with HGP1, but not with HGP2, applied at the early phase of the dissemination process, showed an inhibitory effect on liver metastatization of all the tumor lines studied. Furthermore, one out of the four hexapeptides, BP4 (KRKRKR), had similar activity. Conclusion: Recent data on the antiangiogenic effects of these basic peptides partially explain the in vivo antimetastatic activity. We suggest the small basic penta-hexapeptides as a new class of biological response modifiers which can modulate the metastatic process.",
keywords = "Basic peptide, HGF-β-chain, Liver metastasis",
author = "K. Fazekas and E. R{\'a}s{\'o} and M. Zar{\'a}nd and J. Dud{\'a}s and J. T{\'i}m{\'a}r",
year = "2002",
month = "9",
language = "English",
volume = "22",
pages = "2575--2579",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models

AU - Fazekas, K.

AU - Rásó, E.

AU - Zaránd, M.

AU - Dudás, J.

AU - Tímár, J.

PY - 2002/9

Y1 - 2002/9

N2 - Purpose: We have postulated that the peptide domain(s) of the heparin-binding cytokine(s) might have biological activity, which theoretically could be exploited for modulation of the biological behavior of cancer cells. Materials and Methods: We used HGF as a model heparin-binding cytokine and synthesized two HGF β-chain domains, HHRGK (HGP1) and RYRNKH (HGP2), as well as four variants. As target cells, we used three cancer cell lines (HT25 human colonic, HT168-M1/9 human melanoma and 3LL-HH murine lung carcinoma) all characterized by strong liver metastatic potentials. The effects of peptides on cell proliferation, tumor growth and liver metastasis were evaluated. Results: All the basic penta- or hexapeptides exhibited similar antiproliferative effects in vitro in a dose range of 100-1000 ng/ml. Meanwhile, none of the HGP peptides exhibited significant antitumoral effects on the primary spleen tumors in the form of systemic treatment. However, systemic treatment with HGP1, but not with HGP2, applied at the early phase of the dissemination process, showed an inhibitory effect on liver metastatization of all the tumor lines studied. Furthermore, one out of the four hexapeptides, BP4 (KRKRKR), had similar activity. Conclusion: Recent data on the antiangiogenic effects of these basic peptides partially explain the in vivo antimetastatic activity. We suggest the small basic penta-hexapeptides as a new class of biological response modifiers which can modulate the metastatic process.

AB - Purpose: We have postulated that the peptide domain(s) of the heparin-binding cytokine(s) might have biological activity, which theoretically could be exploited for modulation of the biological behavior of cancer cells. Materials and Methods: We used HGF as a model heparin-binding cytokine and synthesized two HGF β-chain domains, HHRGK (HGP1) and RYRNKH (HGP2), as well as four variants. As target cells, we used three cancer cell lines (HT25 human colonic, HT168-M1/9 human melanoma and 3LL-HH murine lung carcinoma) all characterized by strong liver metastatic potentials. The effects of peptides on cell proliferation, tumor growth and liver metastasis were evaluated. Results: All the basic penta- or hexapeptides exhibited similar antiproliferative effects in vitro in a dose range of 100-1000 ng/ml. Meanwhile, none of the HGP peptides exhibited significant antitumoral effects on the primary spleen tumors in the form of systemic treatment. However, systemic treatment with HGP1, but not with HGP2, applied at the early phase of the dissemination process, showed an inhibitory effect on liver metastatization of all the tumor lines studied. Furthermore, one out of the four hexapeptides, BP4 (KRKRKR), had similar activity. Conclusion: Recent data on the antiangiogenic effects of these basic peptides partially explain the in vivo antimetastatic activity. We suggest the small basic penta-hexapeptides as a new class of biological response modifiers which can modulate the metastatic process.

KW - Basic peptide

KW - HGF-β-chain

KW - Liver metastasis

UR - http://www.scopus.com/inward/record.url?scp=0036765642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765642&partnerID=8YFLogxK

M3 - Article

C2 - 12529966

AN - SCOPUS:0036765642

VL - 22

SP - 2575

EP - 2579

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -